Recombinant Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)
- Datasheet
- References
- Protocols
Overview
-
Product name
Anti-uPA Receptor/U-PAR antibody [EPR22173-257]
See all uPA Receptor/U-PAR primary antibodies -
Description
Rabbit monoclonal [EPR22173-257] to uPA Receptor/U-PAR -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, Flow Cyt, IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human uPA Receptor/U-PAR aa 1 to the C-terminus. The exact sequence is proprietary.
Database link: Q03405 -
Positive control
- ICC/IF: U937 cells treated with 200 nM TPA for 72 hours. Flow Cyt: U937 cells treated with 200 nM TPA for 72 hours. IP: U937 treated with 200 nM TPA for 72 hours whole cell lysate.
-
General notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR22173-257 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab221680 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | 1/100. | |
| Flow Cyt | 1/500. | |
| IP | 1/30. |
Target
-
Function
Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. -
Tissue specificity
Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain. -
Sequence similarities
Contains 3 UPAR/Ly6 domains. -
Cellular localization
Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 5329 Human
- Omim: 173391 Human
- SwissProt: Q03405 Human
- Unigene: 466871 Human
-
Alternative names
- CD 87 antibody
- CD87 antibody
- CD87 antigen antibody
see all
Images
-
![Immunocytochemistry/ Immunofluorescence - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)](https://www.abcam.com/ps/products/221/ab221680/Images/ab221680-319490-anti-upa-receptor-u-par-antibody-epr22173-257-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U937 (human histiocytic lymphoma cell line) cells, untreated or treated with TPA (200 nM, 72 hours), labeling uPA Receptor/U-PAR with ab221680 at 1/100 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).
Confocal image showing membranous staining in U937 cells treated with TPA (200 nM, 72 hours).
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells (PMID:24999729).
The nuclear counterstain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
-
![Flow Cytometry - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)](https://www.abcam.com/ps/products/221/ab221680/Images/ab221680-319491-anti-upa-receptor-u-par-antibody-epr22173-257-flow-cytometry.jpg)
Flow Cytometry - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)Flow cytometric analysis of U937 (human histiocytic lymphoma cell line) cell line treated with 200 nM TPA for 72 hours (red) or Untreated control (green) labeling uPA Receptor/U-PAR with ab221680 at 1/500 dilution compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells (PMID:24999729)
-
![Immunoprecipitation - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)](https://www.abcam.com/ps/products/221/ab221680/Images/ab221680-319492-anti-upa-receptor-u-par-antibody-epr22173-257-immunoprecipitation.jpg)
Immunoprecipitation - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (ab221680)uPA Receptor/U-PAR was immunoprecipitated from 0.35 mg of U937 (human histiocytic lymphoma cell line) treated with 200 nM TPA for 72 hours whole cell lysate with ab221680 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab221680 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.
Lane 1: U937 treated with 200 nM TPA for 72 hours whole cell lysate 10 µg (Input).
Lane 2: ab221680 IP in U937 treated with 200 nM TPA for 72 hours whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab221680 in U937 treated with 200 nM TPA for 72 hours whole cell lysate.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells and the molecular weight is consistent with what has been described in the literature (PMID: 24999729).
Datasheets and documents
References
ab221680 has not yet been referenced specifically in any publications.
